199 related articles for article (PubMed ID: 10878816)
1. Profit at a cost?
Nat Cell Biol; 2000 Jul; 2(7):E113. PubMed ID: 10878816
[No Abstract] [Full Text] [Related]
2. How do you measure "success" in a biotechnology company?
Greetham EM
Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275
[No Abstract] [Full Text] [Related]
3. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
4. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
5. Biotech R&D goes further afield.
Lawrence S
Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
[No Abstract] [Full Text] [Related]
6. Cancer pathways' target not validated by clinical results.
Ratner M
Nat Biotechnol; 1999 Mar; 17(3):220. PubMed ID: 10096279
[No Abstract] [Full Text] [Related]
7. Public biotech 98: the numbers.
Lähteenmäki R; Michael A; Marshall A
Nat Biotechnol; 1999 May; 17(5):429-32. PubMed ID: 10331795
[No Abstract] [Full Text] [Related]
8. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
9. Silent running: the race to the clinic.
Nature; 2006 Aug; 442(7103):614-5. PubMed ID: 16900171
[No Abstract] [Full Text] [Related]
10. Portfolio managing for scientists.
Sable D
Nat Biotechnol; 2010 Oct; 28(10):1131. PubMed ID: 20944607
[No Abstract] [Full Text] [Related]
11. When a long shot is worth a shot.
Jacobs T; Fischer J
Nat Biotechnol; 2005 Jul; 23(7):805. PubMed ID: 16003361
[No Abstract] [Full Text] [Related]
12. Biotechnology in the Medicon Valley.
Frank L
Nature; 2002 Dec; 420(6916 Suppl):A27, A29, A31 passim. PubMed ID: 12501124
[No Abstract] [Full Text] [Related]
13. Differentiating genomics companies.
James R
Nat Biotechnol; 2000 Feb; 18(2):153-5. PubMed ID: 10657119
[TBL] [Abstract][Full Text] [Related]
14. Bridging the gap in the German economy.
Schiermeier Q
Nature; 2005 Aug; 436(7054):1087. PubMed ID: 16127797
[No Abstract] [Full Text] [Related]
15. Fresh horizons South Korea.
Cyranoski D
Nature; 2002 Dec; 420(6916):4-5. PubMed ID: 12478244
[No Abstract] [Full Text] [Related]
16. Stuck in the middle.
Fuyuno I
Nature; 2006 Jul; 442(7100):237. PubMed ID: 16855561
[No Abstract] [Full Text] [Related]
17. Private investment in AIDS vaccine development: obstacles and solutions.
Batson A; Ainsworth M
Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
[TBL] [Abstract][Full Text] [Related]
18. Post-genome, Celera now shoots for profits.
O'Keefe B
Fortune; 2001 Feb; 143(4):226. PubMed ID: 11272265
[No Abstract] [Full Text] [Related]
19. Biotechs hedge against big pharma givebacks.
Dorey E
Nat Biotechnol; 1999 May; 17(5):416-7. PubMed ID: 10331784
[No Abstract] [Full Text] [Related]
20. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
Fiorino T
J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
